[{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Corxel Pharmaceuticals \/ LENZ Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ LENZ Therapeutics"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Corxel Pharmaceuticals \/ LENZ Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ LENZ Therapeutics"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase I","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"6","companyTruncated":"LENZ Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Sectoral Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.080000000000000002,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Sectoral Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ Sectoral Asset Management"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Merger","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ LENZ Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ LENZ Therapeutics"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Graphite Bio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Merger","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Graphite Bio","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ Graphite Bio"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Lotus Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ Lotus Pharmaceutical"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.11,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ Ji Xing Pharmaceuticals"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ RTW Investments"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LENZ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LENZ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LENZ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Ridgeback Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"LENZ Therapeutics \/ Ridgeback Capital","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ Ridgeback Capital"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Aceclidine Hydrochloride","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"Muscarinic receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"LENZ Therapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Aceclidine Hydrochloride
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
